Arab Press

بالشعب و للشعب
Friday, Aug 22, 2025

We'll find a treatment for coronavirus – but drug companies will decide who gets it

We'll find a treatment for coronavirus – but drug companies will decide who gets it

We'll find a treatment for coronavirus – but drug companies will decide who gets it
How will the Covid-19 pandemic end? According to conventional wisdom, the crisis may ease in a few months, when some of the antiviral medicines on trial succeed. In a few years’ time, when a vaccine becomes available, we may eradicate the virus altogether.

Yet it’s unlikely that this is how the pandemic will actually play out. Although there is every indication that treatments for coronavirus may soon emerge, the mere fact of their existence is no guarantee that people will be able to access them. In fact, Covid-19 is more likely to end in the same way that every pandemic ends: treatments and vaccines will be buried in a thicket of patents – and pharmaceutical companies will ultimately make the decisions about who lives and who dies.

We typically think of monopolies, where companies exert exclusive control over a commodity, as market failures that can be corrected with antitrust laws. Medical patents are the equivalent of legalised monopolies. In theory, patents are supposed to grant pharmaceutical companies a reward for investing in research and development. Crucially, they’re supposed to be temporary, lasting for 20 years. But in practice, patenting minor tweaks to a formula can extend this term considerably, foreclosing market competition and granting pharmaceutical companies the power to set prices.

In 1996, a treatment for HIV/Aids was brought to market in the US by a clutch of pharmaceutical companies. The treatment, a combination of antiretroviral medicines, turned a virus that was a death sentence into a chronic condition. It was priced annually at £6,500 per person – in most parts of the world, this price was the same in practice as having no treatment at all. It took until 2004, after millions of people had died from the illness, for India and South Africa to afford the treatment.

Already we’ve seen how medical monopolies have restricted access to coronavirus treatments. We know, for example, that health workers don’t have enough N95 respirator masks; less well known is that 3M holds more than 400 patents for respiratory protection, severely restricting who can produce and supply them in the US. Politicians have called on 3M to release its patents during the pandemic so production can be increased. Amidst an acute shortage of tests for Covid-19, a French diagnostic manufacturer submitted a test kit to the US FDA for emergency approval to sell it in the country, and was sued for patent infringement by a subsidiary of Softbank (this was later withdrawn).

And most of the promising treatments for coronavirus that are being tested in clinical trials have patents attached to them. Some of these, such as favipiravir, which is used to treat influenza, and the combination of Iopinavir and ritonavir, sold under the brand name Kaletra to treat HIV/Aids, have short-term patents in force. Remdesivir, a medicine developed for Ebola by the biotechnology company Gilead, has major patents across the world that last until 2038. Last month, Gilead rushed to secure “orphan drug” status in the US for Remdesivir’s potential use against Covid-19. Orphan status grants companies government incentives to to develop medicines for rare diseases that would otherwise be unprofitable, yet Covid-19 is quite the opposite of a rare disease. The company later backtracked.

There is every possibility that a Covid-19 vaccine will be encumbered with multiple patents. Vaccines are now a big business. Take infant mortality caused by pneumonia, for example. The two vaccines in use today are buried in a thicket of patents belonging to Pfizer and GlaxoSmithKline. India uses the Pfizer vaccine, which retails at $250 for a full course but is available to the government at a discounted rate of £8 through GAVI, the Vaccine Alliance funding. But given that demand in India runs into the tens of millions, even the subsidised cost is unaffordable, and only a small fraction of babies end up getting the vaccine. And so, 40 years after a vaccine for pneumonia was developed, 127,000 Indian babies continue to die from it every year, while the vaccine they can’t afford continues to generate £4.5bn for Pfizer annually.

It’s no surprise that countries are taking pre-emptive measures to deal with monopoly control over medical treatments. Compulsory licensing of patents – a legal measure by which countries can suspend patents on a product – is gaining popularity. Last month, Chile declared that the pandemic justifies the use of compulsory licensing; others soon followed. Israel issued compulsory licenses for lopinavir and ritonavir, Ecuador approved a resolution that asks the minister of health to issue compulsory licences over all patents related to Covid-19, Canada and Germany amended their patent laws to enable the swift grant of a compulsory licence, and Brazil is in the process of amending its patent law to make compulsory licensing easier.

These measures are useful, but they require each country to go it alone. And patents are not the only thing preventing access to coronavirus treatments. Costa Rica recently submitted a proposal to the World Health Organization for a global Covid-19 technology pool – a place where all the necessary intellectual property, such as patents, designs, trade secrets and software could be brought together. The pool would encourage governments to share innovations and make them available globally. The Covid-19 technology pool is far from a done deal, but support for it is growing. Policymakers in the Netherlands and the UK recently threw their weight behind the idea and the director-general of the WHO welcomed Costa Rica’s proposal, while UNITAID has pledged to finance it.

Given that this is a pandemic, it may well be that no corporation can afford to wield the stick for a Covid-19 monopoly. If Covid-19 treatments were free from monopoly control, we would have a real shot at reaching everyone. If this happens – and it’s still a big if – we might realise that such a pharmaceutical system is not only what we need to survive Covid-19, but also what we need to survive other diseases.
Newsletter

Related Articles

Arab Press
0:00
0:00
Close
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
Beijing is moving into gold and other assets, diversifying away from the dollar
Trump Backs Putin’s Land-for-Peace Proposal Amid Kyiv’s Rejection
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
Iranian Protection Offers Chinese Vehicle Shipments a Cost Advantage over Japanese and Korean Makers
United States Sells Luxury Yacht Amadea, Valued at Approximately $325 Million, in First Sale of a Seized Russian Yacht Since the Invasion of Ukraine
Saudi Arabia accelerates renewables to curb domestic oil use
Cristiano Ronaldo and Georgina Rodríguez announce engagement
Asia-Pacific dominates world’s busiest flight routes, with South Korea’s Jeju–Seoul corridor leading global rankings
Private Welsh island with 19th-century fort listed for sale at over £3 million
Sam Altman challenges Elon Musk with plans for Neuralink rival
Australia to Recognize the State of Palestine at UN Assembly
The Collapse of the Programmer Dream: AI Experts Now the Real High-Earners
Armenia and Azerbaijan to Sign US-Brokered Framework Agreement for Nakhchivan Corridor
British Labour Government Utilizes Counter-Terrorism Tools for Social Media Monitoring Against Legitimate Critics
WhatsApp Deletes 6.8 Million Scam Accounts Amid Rising Global Fraud
Texas Residents Face Water Restrictions While AI Data Centers Consume Millions of Gallons
India Rejects U.S. Tariff Threat, Defends Russian Oil Purchases
United States Establishes Strategic Bitcoin Reserve and Digital Asset Stockpile
Thousands of Private ChatGPT Conversations Accidentally Indexed by Google
China Tightens Mineral Controls, Curtailing Critical Inputs for Western Defence Contractors
JPMorgan and Coinbase Unveil Partnership to Let Chase Cardholders Buy Crypto Directly
British Tourist Dies Following Hair Transplant in Turkey, Police Investigate
WhatsApp Users Targeted in New Scam Involving Account Takeovers
Trump Deploys Nuclear Submarines After Threats from Former Russian President Medvedev
Germany’s Economic Breakdown and the Return of Militarization: From Industrial Collapse to a New Offensive Strategy
Germany Enters Fiscal Crisis as Cabinet Approves €174 Billion in New Debt
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
AI Raises Alarms Over Long-Term Job Security
Russia Formally Recognizes Taliban Government in Afghanistan
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Mediators Edge Closer to Israel-Hamas Ceasefire Agreement
Germany Seeks Taliban Deal to Deport Afghan Migrants
Emirates Airline Expands Market Share with New $20 Million Campaign
Robots Compete in Football Tournament in China Amid Injuries
×